REVLAMER 800MG contains Sevelamer carbonate which belongs to a class of medicines called Phosphate binders. It binds phosphate from food in the digestive tract and reduces serum phosphorus levels in the blood. It is used to control hyperphosphataemia in dialysis, for patients undergoing haemodialysis or peritoneal dialysis and with chronic kidney disease who are not on dialysis and have a serum phosphorus level equal to or above 1.78 mmol/l. It works by preventing hyperphosphatemia by binding to dietary phosphate in the gut and thus preventing its absorption and decreases serum phosphate levels.
High levels of serum phosphorus can lead to hard deposits in your body called calcification. These deposits can stiffen your blood vessels and make it harder for blood to be pumped around the body. It can also lead to itchy skin, red eyes, bone pain and fractures.
Take this medicine according to the dose and frequency as advised by your doctor. Swallow it as a whole. Do not chew, crush or break the medicine. This medicine has no or negligible influence on the ability to driving or using machines. It is not recommended for pregnant women and breastfeeding mothers. The most common side effect is constipation. It is not recommended for use in children below 6 years of age.
REVLAMER 800MG works by preventing hyperphosphatemia by binding to dietary phosphate in the gut and thus preventing its absorption and decreases serum phosphate levels.
Take REVLAMER 800MG according to the dose and frequency as advised by your doctor. Swallow it as a whole. Do not chew, crush or break the medicine. It may be taken with food.
Constipation:
Eat fruits, vegetables whole grains and high rich fiber foods.
REVLAMER 800MG should be used with caution in pregnant women. Consult your doctor before taking this medicine.
REVLAMER 800MG should be used with caution during breastfeeding. Consult your doctor before taking this medicine.
This medicine has no or negligible influence on the ability to driving or using machines.
Do not take if you are allergic (hypersensitive) to Sevelamer carbonate.
Inform your doctor if you have,
Tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or the following,
Drug | : | Sevelamer carbonate |
Pharmacological Category | : | Phosphate binder |
Therapeutic Indication | : | Control of serum phosphorous |
Dosage Forms | : | Tablet, Capsule, Powder, Sachet |
Store below 20-25°C and keep out of reach of children.
For how long do I need to consume REVLAMER 800MG?
Take as recommended by your doctor. If you stop suddenly it may result in an increase in your phosphate levels.
Can REVLAMER 800MG be given in children?
This medicine is not recommended for use in children below 6 years of age.
1. Peter A. Friedman. Agents affecting mineral ion homeostasis and bone turnover. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics.12th ed. New York, McGraw-Hill Medical 2011; Page -1293.
2. Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. Page - 1259.
3. Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace & Guido Bellinghieri. Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis: Therapeutics and clinical risk management. Aug 2008; [Accessed Nov 2 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621379/
4. Markus Ketteler, Marianne Rix, Stanley Fan, Nicholas Pritchard, Ove Oestergaard, Scott Chasan Taber, Jeremy Heaton, Ajay Duggal and Philip A. Kalra. Efficacy and Tolerability of Sevelamer Carbonate in Hyperphosphatemic Patients Who Have Chronic Kidney Disease and Are Not on Dialysis. Clinical society of the American journal of nephrology, July 2008; https://cjasn.asnjournals.org/content/clinjasn/3/4/1125.full.pdf
5. Mylan Hungary, Electronic Medicines Compendium (EMC); [Revised June 6, 2019] [Accessed Nov 2, 2020] https://www.medicines.org.uk/emc/files/pil.8784.pdf
6. Genzyme Corporation, 2000; U.S. Food & Drug Administration; [Accessed Nov 2, 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022127s011lbl.pdf
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.